$MYNZ launches its updated ColoAlert version for CRC screening, featuring a new DNA stabilizing buffer which significantly enhances the lab efficiency. Faster results and fewer retests! #stockmarketnews #investing mainzbiomed.com/mainz-biomed…

Mainz Biomed (NASDAQ: MYNZ) secures USD 6M private placement with David Lazar, now Chairman of the Board. The Company is fully committed to advancing pancreatic cancer screening in the U.S. while strategically unlocking long-term value for stockholders. Operations will be streamlined, costs reduced, and runway extended, including the evaluation of colorectal cancer assets and the winding down of the German subsidiary. Press release: mainzbiomed.com/mainz-biomed… $MYNZ $NASDAQ #stockmarkets #stockmarketnews #StocksToWatch #investors

Colorectal cancer is preventable, but nearly 50% of Europeans aged 50–74 aren’t screened. At-home, non-invasive tests remove barriers: ✔️ Earlier detection ✔️ Higher engagement ✔️ More lives saved #cancer #cancerresearch #Health #ScienceWorkingLife #Science

What You Eat Shapes Colorectal Health ✔️ More fiber & calcium ❌ Less processed foods Small daily choices support a healthier gut and lower risk. At Mainz Biomed, we make prevention easy with awareness, healthy habits, and accessible early detection tools. #Healthcare #HealthyHabits #Nutrition #Awareness #CancerResearch $MYNZ $Nasdaq

Imagine catching colorectal cancer early, before it’s too late. 💡 50–74? Ask about at-home screening like ColoAlert. 💡Work in healthcare, HR, or wellbeing? Help raise awareness. Early detection saves lives. Together, prevention is possible. #Cancer #CancerResearch #Science $NASDAQ $MYNZ

Mainz Biomed will be part of AACR 2026, presenting results from our Pancreatic Cancer Verification Study, a key step toward transforming early detection of pancreatic cancer using a blood-based mRNA signature. 📌San Diego | April 17–22 Read more: mainzbiomed.com/mainz-biomed… $MYNZ $NASDAQ #AACR #PancreaticCancer #artificial_intelligence #Science #UnitedStates

At Mainz Biomed, we don’t just study disease. We research, innovate and create non-invasive tests to detect cancer early. $MYNZ $Nasdaq #Health #research

From Mainz Biomed, we want to wish everyone a great 2026 🎉 2025 proved what’s possible with an exceptional team and strong partners. We: ✅Launched eAArly DETECT 2 in the U.S. (~2,000 patients) 🗺️Expanded ColoAlert® across the UK, Switzerland & South America ☑️Advanced pancreatic cancer screening with 100% sensitivity / 95% specificity in feasibility studies In 2026, our focus is clear: complete eAArly DETECT 2 and move ReconAAsense toward FDA approval. Building the future of early cancer detection. Read more: mainzbiomed.com/mainz-biomed… $NASDAQ $MAINZ #stockmarketnews #StocksInFocus #stocks

More and more, it’s becoming clear that what we eat shapes our long-term health, especially our colorectal health Consuming higher levels of ultra-processed foods had a greater risk of developing precancerous colorectal polyps, early growths that can become cancer if unnoticed. That’s why we created ColoAlert, our at-home stool DNA test, an at-home stool DNA test, to make early detection proactive, private, and routine. Because prevention shouldn’t be difficult. It should fit into real life. #HealthyHabits #health #Nutrition #Cancer #CancerResearch #HealthyLiving #NewsUpdate

In the U.S., Mainz Biomed continues advancing our mission in early cancer detection. Our eAArly DETECT 2 study is progressing toward the ReconAAsense FDA pivotal trial for colorectal cancer in 2026. #FDA $MAIZ $NASDAQ #news #BIOTECH #StockMarket #stockmarketnews #Growth #investors

ColoAlert is registered for use across the UK. Bringing faster results and better access to early cancer detection. #uk #UnitedKingdom #BionTech #StocksToWatch #investors #InvestorAlert #Growth #finance2025

Over 112M Americans are 50 , a number projected to reach 157M within the next decade, making early detection of colorectal cancer more important than ever. At Mainz Biomed, we’re dedicated to pioneering innovative diagnostic solutions that make colorectal cancer screening simple, accurate, and accessible for everyone. When testing is within reach, prevention becomes a reality. $MYNZ $NASDAQ #stockmarketnews #Stocks #Marketwatch #MarketNews #UnitedStates

At Mainz Biomed, we believe prevention isn’t passive. It’s proactive, data-driven, and transformative. Through the eAArly DETECT 2 study, we aim to prove that advanced molecular testing can detect precancerous lesions long before disease develops. This changes everything. Because prevention isn’t about waiting, it’s about acting early, with precision and purpose. Together, we can shift global perception: from detecting cancer to preventing it. #Biotech #Health #HealthTech $MYNZ $NASDAQ #StocksToWatch #stockmarketnews

Together with Liquid Biosciences, we used their EMERGE AI platform to identify 18 mRNA biomarkers for pancreatic cancer. The lead panel achieved 100% sensitivity and 95% specificity in a 30-subject study #ArtificialIntelligence #CancerResearch #Research #Health #Algorithms #SciencePerspective #innovation2025 $MYNZ $Nasdaq #StocksToWatch

Science moves us forward. Every day, through research and dedication, we build progress in early cancer detection. We envision a world where colorectal cancer diagnosis becomes prevention, and every test gives hope for a longer, healthier life. #cancer #CancerResearch #CancerCare #HealthcareAI #coloncancer #SciencePerspective #Science #Innovation #ResearchDay2025

Our eAArly DETECT 2 study isn’t just detecting CRC — it’s redefining prevention. Using mRNA biomarkers, FIT and AI, we can catch precancerous lesions early. Prevention is now proactive & powerful. #ColorectalCancer #CancerScreening #BiotechStocks #MedTechInnovation #biomed #prevention

Each year, 37M colorectal screenings are performed in the U.S., expected to rise to 52M in 10 years. Still, nearly 40% of people 50–75 remain unscreened, ~53K deaths annually. Screening at 45 can save lives. #Cancer #CancerResearch #UnitedStates #Health #Mainz $MAINZ $Nasdaq